Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Compass Therapeutics is currently awaiting regulatory feedback on its lead candidate, tovecimig, following positive Phase 2/3 trial results, with a potential BLA filing expected later in 2026.
Compass Therapeutics is preparing for a potential Biologics License Application (BLA) filing for tovecimig in biliary tract cancer later in 2026. The company is currently awaiting FDA feedback on Phase 2/3 COMPANION-002 trial data, which showed statistically significant improvements in progression-free survival.
StockTitan